These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Rhabdoviruses as vectors for vaccines and therapeutics. Scher G; Schnell MJ Curr Opin Virol; 2020 Oct; 44():169-182. PubMed ID: 33130500 [TBL] [Abstract][Full Text] [Related]
6. A vaccinia virus renaissance: new vaccine and immunotherapeutic uses after smallpox eradication. Verardi PH; Titong A; Hagen CJ Hum Vaccin Immunother; 2012 Jul; 8(7):961-70. PubMed ID: 22777090 [TBL] [Abstract][Full Text] [Related]
7. Vesicular stomatitis virus: re-inventing the bullet. Lichty BD; Power AT; Stojdl DF; Bell JC Trends Mol Med; 2004 May; 10(5):210-6. PubMed ID: 15121047 [TBL] [Abstract][Full Text] [Related]
8. Vesicular stomatitis virus as a vector to deliver virus-like particles of human norovirus: a new vaccine candidate against an important noncultivable virus. Ma Y; Li J J Virol; 2011 Mar; 85(6):2942-52. PubMed ID: 21228240 [TBL] [Abstract][Full Text] [Related]
9. Vaccines-all things considered. Part II. 2-3 December 2004, San Francisco, CA, USA. Rosenthal KS IDrugs; 2005 Feb; 8(2):110-1. PubMed ID: 15696409 [No Abstract] [Full Text] [Related]
11. A tool with many applications: vesicular stomatitis virus in research and medicine. Munis AM; Bentley EM; Takeuchi Y Expert Opin Biol Ther; 2020 Oct; 20(10):1187-1201. PubMed ID: 32602788 [TBL] [Abstract][Full Text] [Related]
12. Lassa-vesicular stomatitis chimeric virus safely destroys brain tumors. Wollmann G; Drokhlyansky E; Davis JN; Cepko C; van den Pol AN J Virol; 2015 Jul; 89(13):6711-24. PubMed ID: 25878115 [TBL] [Abstract][Full Text] [Related]
13. Letter from the Editor. Ellis R; Weiss A Hum Vaccin Immunother; 2015; 11(6):1297. PubMed ID: 26086583 [No Abstract] [Full Text] [Related]
14. Chikungunya, Influenza, Nipah, and Semliki Forest Chimeric Viruses with Vesicular Stomatitis Virus: Actions in the Brain. van den Pol AN; Mao G; Chattopadhyay A; Rose JK; Davis JN J Virol; 2017 Mar; 91(6):. PubMed ID: 28077641 [TBL] [Abstract][Full Text] [Related]
15. Attenuation of recombinant vesicular stomatitis virus-human immunodeficiency virus type 1 vaccine vectors by gene translocations and g gene truncation reduces neurovirulence and enhances immunogenicity in mice. Cooper D; Wright KJ; Calderon PC; Guo M; Nasar F; Johnson JE; Coleman JW; Lee M; Kotash C; Yurgelonis I; Natuk RJ; Hendry RM; Udem SA; Clarke DK J Virol; 2008 Jan; 82(1):207-19. PubMed ID: 17942549 [TBL] [Abstract][Full Text] [Related]
16. Vesicular stomatitis virus as a treatment for colorectal cancer. Stewart JH; Ahmed M; Northrup SA; Willingham M; Lyles DS Cancer Gene Ther; 2011 Dec; 18(12):837-49. PubMed ID: 21886191 [TBL] [Abstract][Full Text] [Related]
17. A lethal mice model of recombinant vesicular stomatitis viruses for EBOV-targeting prophylactic vaccines evaluation. Zhang HQ; Zhang ZR; Deng CL; Yuan ZM; Zhang B Virol Sin; 2024 Jun; 39(3):516-519. PubMed ID: 38522616 [TBL] [Abstract][Full Text] [Related]
18. Vaccination with Vesicular Stomatitis Virus-Vectored Chimeric Hemagglutinins Protects Mice against Divergent Influenza Virus Challenge Strains. Ryder AB; Nachbagauer R; Buonocore L; Palese P; Krammer F; Rose JK J Virol; 2015 Dec; 90(5):2544-50. PubMed ID: 26676789 [TBL] [Abstract][Full Text] [Related]